The SEC filings page for OnKure Therapeutics, Inc. (OKUR) provides access to the company’s official regulatory disclosures as a clinical-stage biopharmaceutical issuer listed on the Nasdaq Global Market. These documents offer detailed information about its precision oncology programs, financial condition, and capital markets activities, complementing the high-level descriptions found in press releases.
Through its periodic reports on Forms 10-K and 10-Q, OnKure describes its focus on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by current therapies. These filings expand on the company’s strategy around PI3Kα-targeted programs, including its lead candidate OKI-219 and its PI3Kα pan-mutant and other discovery-stage efforts, and include sections such as “Risk Factors” that outline scientific, clinical, regulatory, and financial risks.
Current reports on Form 8-K capture material events between periodic filings. For example, OnKure has filed 8-Ks to report quarterly financial results and to disclose entry into a sales agreement with Leerink Partners LLC for an at-the-market offering program of its Class A common stock. That agreement allows the company, subject to specified parameters and an effective shelf registration statement on Form S-3, to sell shares through Leerink Partners acting as sales agent, with compensation based on a percentage of gross proceeds.
On this page, users can review new and historical SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and registration statements such as Form S-3 referenced in the at-the-market program. Stock Titan’s tools apply AI-powered summaries to help explain the contents of lengthy filings, highlight key items like clinical development updates, capital raising arrangements, and risk disclosures, and make it easier to track how OnKure’s regulatory narrative evolves over time.
OnKure Therapeutics director R. Michael Carruthers received a new stock option grant. On June 4, 2026, he was granted options covering 7,650 shares of Class A common stock at an exercise price of $4.30 per share.
All 7,650 option shares will vest on the earlier of June 4, 2027 or the day before OnKure’s next annual stockholder meeting, as long as he continues as a service provider through that date. After this grant, he holds options for 7,650 shares directly, with an expiration date of June 3, 2036.
OnKure Therapeutics held its 2026 annual stockholder meeting and approved amendments to its 2024 Equity Incentive Plan. The plan now includes a one-time increase of 3,231,638 shares of common stock, described as approximately 8% of outstanding shares, reserved for equity awards.
The annual “evergreen” feature will continue to add up to 5% of outstanding shares each year, but the prior numerical cap of 2,407,100 shares has been removed, and the number of shares eligible for incentive stock options is now limited. Shareholders also elected three Class II directors to serve until the 2029 annual meeting, ratified KPMG LLP as independent auditor for 2026, and formally approved the amended and restated 2024 Equity Incentive Plan.
OnKure Therapeutics reports ownership disclosures by the BVF group. As of May 27, 2026, the Reporting Persons disclose beneficial ownership aggregating 2,134,908 Shares of Class A Common Stock and hold pre-funded warrants exercisable for an aggregate of 2,147,534 Shares, subject to the 4.9% Pre-Funded Warrants Blocker.
The filing ties percentages to a base of 40,395,480 Shares outstanding as of May 4, 2026, showing individual reported stakes: BVF 1,095,373 Shares (≈ 2.7%), BVF2 854,705 Shares (≈ 2.1%) and Trading Fund OS 153,595 Shares (<1%). The Pre-Funded Warrants are exercisable immediately but currently blocked by the 4.9% limit.
OnKure Therapeutics, Inc. Schedule 13G/A reports that ADAR1-related reporting persons and Daniel Schneeberger beneficially own 2,434,941 shares of Class A Common Stock, representing 6.0% of the class, based on 40,395,480 shares outstanding as of March 31, 2026.
The filing states the 2,434,941 figure reflects aggregated holdings across ADAR1 Partners, LP; Spearhead Insurance Solutions IDF, LLC; and other separately managed accounts, and that Mr. Schneeberger may be deemed an indirect beneficial owner as manager and control person. The share counts and the March 31, 2026 time anchor are cited from the filing and the issuer's Form 10-Q reported on May 5, 2026.
OnKure Therapeutics reported first quarter 2026 results and highlighted a major capital raise and pipeline refocus. Cash and cash equivalents were $192.1 million as of March 31, 2026, including proceeds from an oversubscribed $150 million private placement, which the company expects will fund operations into 2029.
Research and development expenses were $11.7 million and general and administrative expenses were $3.9 million, both slightly lower than the prior-year quarter. Net loss was $15.2 million, or $1.11 per share, compared with $15.9 million, or $1.19 per share, a year earlier.
Strategically, OnKure nominated two next-generation PI3Kα pan-mutant selective inhibitor candidates, OKI-355 for vascular anomalies and OKI-345 for breast cancer, with plans to submit IND applications for both in the first half of 2027. The company is not planning to independently pursue further clinical development of OKI-219 but will report data from the PIKture-01 study by the end of 2026.
OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision small-molecule drugs targeting mutant PI3Kα for cancers and vascular anomalies. It reported a net loss of $15.2 million for the quarter ended March 31, 2026, slightly improved from $15.9 million a year earlier, as research and development expenses decreased to $11.7 million and general and administrative costs held roughly flat at $3.9 million.
A key event was a private placement completed on March 31, 2026, providing approximately $150.0 million in gross proceeds through the sale of 26,713,638 Class A shares at $4.15 per share and 9,430,957 pre-funded warrants at $4.1499 per underlying share. After this financing, cash and cash equivalents rose to $192.1 million from $59.1 million at year-end 2025, and management now believes available cash will fund the current operating plan for at least 12 months.
As of May 4, 2026, there were 40,395,480 Class A shares outstanding, reflecting significant dilution from equity issuances. OnKure is prioritizing next-generation PI3Kα pan-mutant programs OKI-345 and OKI-355, while not planning further independent clinical development of OKI-219. The company continues to operate at a loss and anticipates increased spending as its pipeline progresses.
OnKure Therapeutics, Inc. has filed a shelf registration to permit the resale by selling stockholders of up to 36,144,595 shares of Class A common stock. The shares consist of 26,713,638 outstanding shares and 9,430,957 shares issuable upon exercise of pre-funded warrants issued in a private placement closed March 31, 2026. The company states it will not receive proceeds from resales under this prospectus; however, it will receive proceeds if pre-funded warrants are exercised for cash. The prospectus notes 40,395,480 shares outstanding as of April 1, 2026 and a Beneficial Ownership Limitation tied to pre-funded warrant exercises (default 19.99%).
OnKure Therapeutics, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on director elections, auditor ratification and a major update to its equity plan. Holders of 40,395,480 shares of Class A Common Stock as of April 16, 2026 may vote, one vote per share.
Stockholders will elect three Class II directors (R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers) to terms ending at the 2029 meeting and vote on ratifying KPMG LLP as independent auditor for the year ending December 31, 2026. The meeting will be held online on June 3, 2026 at 9:00 a.m. Eastern Time.
A key item is approval of an amended and restated 2024 Equity Incentive Plan, which would add 3,231,638 shares (about 8% of outstanding shares) to the plan’s reserve, remove the 2,407,100‑share annual cap in the evergreen provision (after a 1:10 reverse split), and introduce a limit on incentive stock options. The board cites dilution from a March 2026 $150.0 million PIPE financing, in which 26,713,638 shares were sold, and the resulting fall of employee ownership below the 25th percentile of peers, as reasons to expand equity capacity to support recruitment, retention and long‑term incentives.